Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs).

Autor: Thomas K; Division of Hematology/Oncology, Louisiana State University Health Science Center, New Orleans, LA 70112, USA., Voros BA; Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.; Ochsner Medical Center-Kenner, Neuroendocrine Tumor Clinic, Kenner, LA 70065, USA., Meadows-Taylor M; Department of Epidemiology and Biostatistics, University of Memphis School of Public Health, Memphis, TN 20910, USA., Smeltzer MP; Department of Epidemiology and Biostatistics, University of Memphis School of Public Health, Memphis, TN 20910, USA., Griffin R; Ochsner Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, New Orleans, LA 70122, USA., Boudreaux JP; Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.; Ochsner Medical Center-Kenner, Neuroendocrine Tumor Clinic, Kenner, LA 70065, USA., Thiagarajan R; Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.; Ochsner Medical Center-Kenner, Neuroendocrine Tumor Clinic, Kenner, LA 70065, USA., Woltering EA; Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.; Ochsner Medical Center-Kenner, Neuroendocrine Tumor Clinic, Kenner, LA 70065, USA., Ramirez RA; Ochsner Medical Center-Kenner, Neuroendocrine Tumor Clinic, Kenner, LA 70065, USA.; Ochsner Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, New Orleans, LA 70122, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2020 Jan 14; Vol. 12 (1). Date of Electronic Publication: 2020 Jan 14.
DOI: 10.3390/cancers12010206
Abstrakt: Capecitabine and temozolomide (CAPTEM) have shown promising results in the treatment of neuroendocrine neoplasms (NEN). The aim of this study was to evaluate the outcome and role for CAPTEM in malignant neuroendocrine neoplasms. Data were obtained from NEN patients who received at least one cycle of CAPTEM between November 2010 and June 2018. The average number of cycles was 9.5. For analysis, 116 patients were included, of which 105 patients (91%) underwent prior treatment. Median progression free survival (PFS) and overall survival (OS) were 13 and 38 months, respectively. Overall response rate (ORR) was 21%. Disease control rate (DCR) was 73% in all patients. PFS, median OS, ORR, and DCR for pancreatic NENs (pNEN) vs. non-pNEN was 29 vs. 11 months, 35 vs. 38 months, 38% vs. 9%, and 77% vs. 71%, respectively. Patients with pNEN had a 50% lower hazard of disease progression compared to those with non-pNEN (adjusted Hazard Ratio: 0.498, p = 0.0100). A significant difference in PFS was found between Ki-67 < 3%, Ki-67 3-20%, Ki-67 > 20-54%, and Ki-67 ≥ 55% (29 vs. 12 vs. 7 vs. 5 months; p = 0.0287). Adverse events occurred in 74 patients (64%). Our results indicate that CAPTEM is associated with encouraging PFS, OS, and ORR data in patients with NENs.
Competing Interests: The authors declare no conflicts of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje